Precigen, Inc. (PGEN)

1.4000 0.0000 (0.00%) At close: 04:00PM EDT

Precigen, Inc.

20374 Seneca Meadows Parkway
Germantown, MD 20876
United States
301 556 9900
https://precigen.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 209

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Randal J. Kirk J.D.	Exec. Chairman	100k	N/A	1953
Dr. Helen Sabzevari MPH, Ph.D.	Pres, CEO & Director	1.29M	N/A	1962
Mr. Harry Thomasian Jr.	Chief Financial Officer	524.04k	N/A	1963
Mr. Rutul R. Shah	Chief Operating Officer	393.54k	N/A	1981
Mr. Donald P. Lehr	Chief Legal Officer & Corp. Sec.	652.4k	N/A	1975
Mr. Jeffrey Thomas Perez	Sr. VP of Intellectual Property Affairs	570.24k	N/A	1972
Dr. Thomas D. Reed Ph.D.	Founder & Chief Science Officer	N/A	N/A	1966
Mr. Steven Harasym	VP & Head of Investor Relations	N/A	N/A	N/A
Marie Rossi	VP of Communications	N/A	N/A	N/A
Mr. Rob Russell	VP & Head of HR	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Corporate governance

Precigen, Inc.’s ISS governance QualityScore as of 1 September 2023 is 5. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.